Dexmedetomidine extraction by the extracorporeal membrane oxygenation circuit: results from an in vitro study

Abstract

Background:

Dexmedetomidine is a sedative administered to minimize distress and decrease the risk of life threatening complications in children supported with extracorporeal membrane oxygenation. The extracorporeal membrane oxygenation circuit can extract drug and decrease drug exposure, placing the patient at risk of therapeutic failure.

Objective:

To determine the extraction of dexmedetomidine by the extracorporeal membrane oxygenation circuit.

Materials and methods:

Dexmedetomidine was studied in three closed-loop circuit configurations to isolate the impact of the oxygenator, hemofilter, and tubing on circuit extraction. Each circuit was primed with human blood according to standard practice for Duke Children’s Hospital, and flow was set to 1 L/min. Dexmedetomidine was dosed to achieve a therapeutic concentration of ~600 pg/mL. Dexmedetomidine was added to a separate tube of blood to serve as a control and evaluate for natural drug degradation. Serial blood samples were collected over 24 hours and concentrations were quantified with a validated assay. Drug recovery was calculated at each time point.

Results:

Dexmedetomidine was highly extracted by the oxygenator evidenced by a mean recovery of 62-67% at 4 hours and 23-34% at 24 hours in circuits with an oxygenator in-line. In contrast, mean recovery with the oxygenator removed was 96% at 4 hours and 93% at 24 hours. Dexmedetomidine was stable over time with a mean recovery in the control samples of 102% at 24 hours.

Conclusion:

These results suggest dexmedetomidine is extracted by the oxygenator in the extracorporeal membrane oxygenation circuit which may result in decreased drug exposure in vivo.

Keywords

sedative extraction extracorporeal membrane oxygenation dexmedetomidine precedex

Get full access to this article

View all access options for this article.

References

Tobias

JD.

Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med 2007; 8: 115–131.

Sulton

McCracken

Simon

et al. Pediatric procedural sedation using dexmedetomidine: a report from the Pediatric Sedation Research Consortium. Hosp Pediatr 2016; 6: 536–544.

Whalen

Di Gennaro

Irby

et al. Long-term dexmedetomidine use and safety profile among critically ill children and neonates. Pediatr Crit Care Med 2014; 15: 706–714.

Hayden

Breatnach

Doherty

et al. Efficacy of alpha2-agonists for sedation in pediatric critical care: a systematic review. Pediatr Crit Care Med 2016; 17: e66–75.

Tobias

Berkenbosch

JW.

Initial experience with dexmedetomidine in paediatric-aged patients. Paediatr Anaesth 2002; 12: 171–175.

Reiter

Pietras

Dobyns

EL.

Prolonged dexmedetomidine infusions in critically ill infants and children. Indian Pediatr 2009; 46: 767–773.

Chrysostomou

Di Filippo

Manrique

et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med 2006; 7: 126–131.

Gupta

Whiteside

Sabati

et al. Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease. Pediatr Crit Care Med 2012; 13: 660–666.

Tobias

Berkenbosch

JW.

Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. South Med J 2004; 97: 451–455.

10.

Shekar

Roberts

Mcdonald

et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care 2015; 19: 164.

11.

Geiduschek

Lynn

Bratton

et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 1997; 25: 360–364.

12.

Dagan

Klein

Bohn

et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med 1994; 22: 1099–1101.

13.

Hynynen

Binding of fentanyl and alfentanil to the extracorporeal circuit. Acta Anaesthesiol Scand 1987; 31: 706–710.

14.

Bentley

Conahan

3rd Cork

RC.

Fentanyl sequestration in lungs during cardiopulmonary bypass. Clin Pharmacol Ther 1983; 34: 703–706.

15.

Dagan

Klein

Gruenwald

et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993; 15: 263–266.

16.

Bhatt-Meht

Annich

Sedative clearance during extracorporeal membrane oxygenation. Perfusion 2005; 20: 309–315.

17.

Peters

Anderson

Simons

et al. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006; 45: 705–714.

18.

Peters

Anderson

Simons

et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med 2005; 31: 257–263.

19.

Mulla

Lawson

Peek

et al. Plasma concentrations of midazolam in neonates receiving extracorporeal membrane oxygenation. ASAIO J 2003; 49: 41–47.

20.

Lemaitre

Hasni

Leprince

et al. Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care 2015; 19: 40.

21.

Wildschut

Ahsman

Allegaert

et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010; 36: 2109–2116.

22.

Rosen

Silvasi

DL.

In vitro variability in fentanyl absorption by different membrane oxygenators. J Cardiothorac Anesth 1990; 4: 332–335.

23.

Watt

Cohen-Wolkowiez

Williams

et al. Antifungal extraction by the extracorporeal membrane oxygenation circuit. J Extra Corpor Technol 2017; 49: 150–159.

24.

Wishart

Feunang

Guo

et al.DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 2018; 46: D1074–D1082.

25.

Wagner

Pasko

Phillips

et al. In vitro clearance of dexmedetomidine in extracorporeal membrane oxygenation. Perfusion 2013; 28: 40–46.

26.

Park

Shin

Lee

et al. Investigation of key circuit constituents affecting drug sequestration during extracorporeal membrane oxygenation treatment. ASAIO J 2016; 63: 293–298.

27.

Greenberg

Laughon

et al. Population pharmacokinetics of dexmedetomidine in infants. J Clin Pharmacol 2017; 57: 1174–1182.

28.

Potts

Anderson

Warman

et al. Dexmedetomidine pharmacokinetics in pediatric intensive care—a pooled analysis. Paediatr Anaesth 2009; 19: 1119–1129.

29.

U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine. Bioanalytical Method Validation: Guidance for Industry. Rockville, MD, 2013, https://www.fda.gov/media/70858/download

30.

Harthan

Buckley

Heger

et al. Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Ther 2014; 19: 288–295.

31.

Millar

Fanning

McDonald

et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care 2016; 20: 387.

32.

Yamasaki

Hayashi

Nakatani

et al. Early experience with low-prime (99 ml) extracorporeal membrane oxygenation support in children. ASAIO J 2006; 52: 110–114.

33.

Zwiers

deWildt

Hop

et al. Acute kidney injury is a frequent complication in critically ill neonates receiving extracorporeal membrane oxygenation: a 14-year cohort study. Crit Care 2013; 17: R151.

34.

Smith

Hardison

Worden

et al. Acute renal failure during extracorporeal support in the pediatric cardiac patient. ASAIO J 2009; 55: 412–416.

35.

Preston

Ratliff

Gomez

et al. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol 2010; 42: 199–202.

36.

Myers

Voorhees

Eke

et al. The effect of Diprivan (propofol) on phosphorylcholine surfaces during cardiopulmonary bypass—an in vitro investigation. Perfusion 2009; 24: 349–355.

37.

Palmgren

Monkkonen

Korjamo

et al. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 2006; 64: 369–378.

38.

Buck

ML.

Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003; 42: 403–417.